Expanding the availability of medication treatment for opioid use disorder in primary care settings would be a major step toward reducing overdose deaths, write two physicians specializing in addiction medicine and health-care delivery in the July 5 issue of New England Journal of Medicine. In their Perspectives article entitled “Primary Care and the Opioid-Overdose Crisis—Buprenorphine Myths and Realities,” Sarah Wakeman, MD, medical director of the Massachusetts General Hospital Substance Use Disorders Initiative and Michael Barnett, MD, of the Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, describe current barriers to expanded delivery of buprenorphine treatment and outline possible solutions.

“One of the tragic ironies is that with well-established medical treatment, opioid use disorder can have an excellent prognosis,” they write, noting that almost 80% of Americans with opioid use disorder are unable to receive treatment and that the growth in distribution of buprenorphine—one of three FDA-approved medications for the treatment of opioid use disorder—has been slowing rather than increasing in recent years. “To have any hope of stemming the overdose tide, we have to make it easier to obtain buprenorphine than to get heroin and fentanyl.”

The authors describe five persistent, but inaccurate, myths that they believe prevent buprenorphine from being more widely adopted:

•That it's more dangerous that other common health-care interventions,
•That buprenorphine treatment is just replacing one addition for another,
•That abstinence-based treatment—short-term detoxification and rehabilitation—is more effective than medication-based treatment,
•That providing buprenorphine treatment is particularly onerous and time-consuming for primary care physicians (PCPs),
•That physicians should just reduce opioid prescriptions to address the overdose epidemic.

Most outpatient buprenorphine treatment is already provided by PCPs, and expanding the availability of office-based buprenorphine treatment, as several other countries have done, presents a realistic solution to addressing the overdose crisis, the authors note. They write, “We are in the midst of a historic public health crisis that demands action from every physician. Without dramatic intervention, life expectancy in the United States will continue to decline. Mobilizing the PCP workforce to offer office-based buprenorphine treatment is a plausible, practical, and scalable intervention that could be implemented immediately.”